Tamoxifen is an effective treatment for hormone receptor-positive breast cancer (BC)
. Despite its effectiveness, there have been many reports of adverse reaction. However, the relationship between Tamoxifen-related adverse events (ADEs) and patient age remains unclear.
Aim
To enhance clinical medication guidance and drug safety by identifying age-specific ADEs associated with Tamoxifen therapy in female breast cancer patients, thereby offering a more robust foundation for evidence-based clinical practice
.
Methods
ADEs reports of Tamoxifen from the FAERS database were extracted from the first quarter of 2004 to the second quarter of 2023. Reporting odds ratio (ROR) data analysis strategy was used for mining signal strength that represents age differences in ADEs related to Tamoxifen.
Results
The number of efficient ADE signals associated with Tamoxifen for female BC included in the analysis was 338 in premenopausal women, 847 in perimenopause and 1525 in postmenopause respectively. Our study showed age differences in three age groups of ADEs with Tamoxifen in female BC. Perimenopausal and postmenopausal women receiving tamoxifen therapy demonstrated a significantly higher incidence of adverse drug reactions, particularly involving the gastrointestinal tract, renal/urinary systems, hematologic/lymphatic systems, endocrine functions, and immune responses. It was particularly concerned that ADEs associated with ear and labyrinth disorders had only been reported in perimenopause.
Conclusion
Age differences was detected in ADE signals related to Tamoxifen. There were significant differences in Tamoxifen related ADEs of premenopausal, perimenopausal and postmenopausal women with BC in different systems. To ensure the safety of medicines, we should be aware of the age-related differences in ADEs and take appropriate preventive measures to reduce incidence of serious ADEs.
AcheampongTKehmRDTerryMB, et al.Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open2020; 3: e2013226.
2.
YuAYLThomasSMDiLallaGD. Disease characteristics & mortality among Asian women with breast cancer. Cancer2022; 5: 1024–1037.
3.
AndrahennadiSSamiAMannaM, et al.Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer. Curr Oncol2021; 28: 1803–1822.
4.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005; 365: 1687–1717.
5.
BursteinHJLacchettiCAndersonH, et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol2016; 34: 1689–1701.
6.
StearnsVGelmannEP. Does Tamoxifen cause cancer in humans. J Clin Oncol1998; 2: 779–792.
7.
JagerNGLinnSCSchellensJH, et al.Tailored Tamoxifen treatment for breast cancer patients: a perspective. Clin Breast Cancer2015; 15: 241–244.
8.
DaviesCGodwinJGrayR.Relevance of breast cancer hormone receptors and other factors to the effi cacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 2011; 9793: 771–784.
TanakaJKosekiTKondoM.Analyses of ocular adverse reactions associated with anticancer drugs based on the Japanese pharmacovigilance database. Anticancer Res2022; 9: 4439–4451.
11.
MouritsMJDe VriesEGWillemsePH. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol2001; 5(Pt 2): 855–866.
12.
KenslerKHEliassenAHRosnerBA, et al.Pre-diagnostic sex hormone levels and survival among breast cancer patients. Breast Cancer Res Treat2019; 174: 749–758.
13.
ParlFFCrookePSPlummerWJ, et al.Genomic-Epidemiologic evidence that estrogens promote breast cancer development. Cancer Epidemiol Biomarkers Prev2018; 27: 899–907.
14.
MoyerAMMateyETMillerVM. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol Res Perspect2019; 7: e541.
15.
SetyawanJAzimiNStrandV, et al.Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019. Drug Saf2021; 44: 889–897.
16.
MontastrucJLSommetABagheriH, et al.Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol2011; 72: 905–908.
17.
ShinoharaCItoKTakamatsuK.Factors associated with xerostomia in perimenopausal women. J Obstet Gynaecol Res2021; 10: 3661–3668.
18.
KupcewiczEDrezek-SkrzeszewskaMRoszukW, et al.Relationship between frequency and intensity of menopausal symptoms and quality of life among Polish nurses. Risk Manag Healthc Policy2021; 14: 97–107.
19.
de KatACDamVOnland-MoretNC, et al.Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study. BMC Med2017; 15: 2.
AkhtarTFrattiJDCMattumpuramJ.Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation，A real-world experience. Int J Cardiol2020; 320: 78–82.
22.
GradisharWJMoranMSAbrahamJ.Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw2022; 6: 691–722.
23.
DackusGMHEJóźwiakKSonkeGS, et al.Adjuvant aromatase inhibitors or Tamoxifen following chemotherapy for perimenopausal breast cancer patients. JNCI: J Natl Cancer Inst2021; 113: 1506–1514.
24.
MorrisonLLoiblSTurnerNC. The CDK4_6 inhibitor revolution – a game-changing era for breast cancer treatment. Nat Rev Clin Oncol2024; 2: 89–105.
25.
BrandaoMCaparicaREigerD, et al.Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol2019; 30(Suppl_10): x27–x42.
26.
HarbeckNGM. Breast cancer. Lancet2017; 10074: 1134–1150.
27.
WibowoEPollockPAHollisN, et al.Tamoxifen in men: a review of adverse events. Andrology (Oxford)2016; 4: 776–788.
28.
BuijsSMKoolenSLWMathijssenRHJ, et al.Tamoxifen dose de-escalation: an effective strategy for reducing adverse effects?. Drugs (New York, N.Y.)2024; 84: 385–401.
29.
de Vries SchultinkAHMZwartWLinnSC, et al.Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of Tamoxifen. Clin Pharmacokinet2015; 54: 797–810.
30.
KeCChenMLinL. Postmarketing adverse events of tamoxifen in male and female patients with breast cancer. Int J Cancer2025; 4: 734–743.
31.
AnandKEnsorJTrachtenbergB.Osimertinib-Induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol2019; 2: 172–178.
32.
YinYShuYZhuJ, et al.A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci Rep2022; 12: 19511–19555.
33.
MarlattKLPitynski-MillerDRGavinKM. Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring)2022; 1: 14–27.
34.
LiznevaDYuenTSunL. Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition. Matrix Biol2018; 71–72: 70–81.
35.
TsarasKPapathanasiouIVMitsiD, et al.Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. Asian Pac J Cancer Prev2018; 19: 1661–1669.
36.
CarreiraHWilliamsRMüllerM, et al.Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review. JNCI: J Natl Cancer Inst2018; 110: 1311–1327.
37.
BijsterboschJMvan den BrinkFVollmannM, et al.Understanding relations between intolerance of uncertainty, social anxiety, and body dissatisfaction in women. J Nerv Ment Dis2020; 208: 833–835.
38.
CookEERosenbergSMRuddyKJ, et al.Prospective evaluation of the impact of stress, anxiety, and depression on household income among young women with early breast cancer from the young and strong trial. BMC Public Health2020; 20: 1514.
39.
LinHLHsiaoMCLiuYT, et al.Perimenopause and incidence of depression in midlife women: a population-based study in Taiwan. Climacteric2013; 16: 381–386.
40.
de KruifMSpijkerATMolendijkML. Depression during the perimenopause: a meta-analysis. J Affect Disord2016; 206: 174–180.
41.
CarusoDMasciICipolloneG, et al.Insomnia and depressive symptoms during the menopausal transition: theoretical and therapeutic implications of a self-reinforcing feedback loop. Maturitas2019; 123: 78–81.
42.
PakenJGovenderCDSewramV. Research protocol: cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program. BMC Womens Health2017; 17: 129.
43.
JenkinsVBeveridgeHLowR, et al.Atypical hearing loss in women with breast cancer receiving adjuvant treatment. Breast (Edinburgh)2006; 15: 447–450.
44.
JillellaAPBrittGWLitakerMS, et al.Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer. Med Oncol2000; 17: 287–292.
45.
SarafrazMAhmadiK. Paraclinical evaluation of side-effects of Taxanes on auditory system. Acta Otorhino-Laryngologica italica2008; 28: 239–242.
46.
GeueKGobelPLeuteritzK, et al.Anxiety and depression in young adult German cancer patients: time course and associated factors. Psychooncology2019; 28: 2083–2090.
47.
TroìaLMartoneSMorganteG, et al.Management of perimenopause disorders: hormonal treatment. Gynecol Endocrinol2021; 37: 195–200.
48.
DeecherDCDorriesK. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health2007; 10: 247–257.
49.
SouwerESanchez-SpitmanAMoesD, et al.Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer. Breast Cancer Res Treat2023; 199: 471–478.
50.
LiZZouWYuanJ.Gender differences in adverse events related to osimertinib_ a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opin Drug Saf2023; 31: 1–8.
51.
MicaleCGolderSO’ConnorK.Patient-Reported reasons for antihypertensive medication change_ A quantitative study using social Media. Drug Saf2024; 1: 81–91.
52.
SouwerETDSanchez-SpitmanAMoesDJAR. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer (1). Breast Cancer Res Treat2023; 3: 471–478.
53.
MirandaCGalleguillosMTorresR, et al.Preliminary pharmacogenomic-based predictive models of Tamoxifen response in hormone-dependent Chilean breast cancer patients. Front Pharmacol2021; 12: 661443.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
